4
Changes in Ownership
MADRIGAL PHARMACEUTICALS, INC. Filed Acc 0000950170-24-043503
Pres., R&D, and CMO sold 2,676 shares at an average $245.99 ($658,258)
- Pres., R&D, and CMO acquired 2,676 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Taub Rebecca Pres., R&D, and CMO | 2024-04-08 | Option exercise 10b5-1 | +2,676 | $9.45 | $25,288 | 461,675 | D |
| Taub Rebecca Pres., R&D, and CMO | 2024-04-08 | Sale 10b5-1 | −224 | $243.25 | $54,487 | 461,451 | D |
| Taub Rebecca Pres., R&D, and CMO | 2024-04-08 | Sale 10b5-1 | −945 | $244.79 | $231,325 | 460,506 | D |
| Taub Rebecca Pres., R&D, and CMO | 2024-04-08 | Sale 10b5-1 | −300 | $245.69 | $73,706 | 460,206 | D |
| Taub Rebecca Pres., R&D, and CMO | 2024-04-08 | Sale 10b5-1 | −600 | $246.98 | $148,186 | 459,606 | D |
| Taub Rebecca Pres., R&D, and CMO | 2024-04-08 | Sale 10b5-1 | −407 | $247.76 | $100,838 | 459,199 | D |
| Taub Rebecca Pres., R&D, and CMO | 2024-04-08 | Sale 10b5-1 | −200 | $248.58 | $49,716 | 458,999 | D |
| Derivatives | |||||||
| Taub Rebecca Pres., R&D, and CMO | 2024-04-08 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,676 | 76,564 | D | ||
| Open-market sales · 2,676 sh · avg $245.99 · $658,258 | |||||||
Loading xslF345X05/ownership.xml…